CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 305 enrolled
Drug / intervention
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01984242
NCT01984242Phase 2Completed
CompareCT.gov

A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

Hoffmann-La Roche·interventional·Posted Nov 14, 2013·Updated Dec 23, 2019

In Brief

A Phase 2 clinical trial evaluating Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Bevacizumab, and 1 other intervention for Renal Cell Carcinoma. Completed, enrolled 305 participants across 45 sites in 9 countries.

Detailed Summary

This multicenter, randomized, open-label study will evaluate the efficacy, safety and tolerability of atezolizumab as monotherapy or in combination with bevacizumab versus sunitinib in participants with histologically confirmed, inoperable, locally advanced or metastatic renal cell carcinoma who have not received prior systemic therapy either in the adjuvant or metastatic setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesCzechia, France, Germany, Italy, Poland, Romania, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 14, 2013
Enrollment StartJan 8, 2014
Primary CompletionOct 17, 2016
Study CompletionJan 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.6 years ago

Interventions

Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibodydrug

Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.

Bevacizumabdrug

Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.

Sunitinibdrug

Sunitinib will be administered according to the dosage schedule mentioned in the arm description.